The Medical Letter on Drugs and Therapeutics
Zafirlukast for Asthma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Zafirlukast for Asthma
Zafirlukast (za fir loo kast; Accolate - Zeneca), the first leukotriene receptor anta-gonist approved by the US Food and Drug Administration, is now being heavily promoted for oral maintenance treatment of chronic asthma in patients more than 12...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Zafirlukast for Asthma
Article code: 990a
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.